Clinical trials: Proteinuria
IGA Nephropathy
Mycophenolate Mofetil for IgA Nephropathy
IgA nephropathy (IgAN) is the commonest primary glomerulonephritis worldwide. In Hong Kong, IgAN accounts for approximately 30% of all primary glomerular diseases, and a significant proportion of young patients (< 50 years of…
- Trial name
- NCT00863252
- Testing
- mycophenolate mofetil, angiotensin blockade
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The University of Hong Kong
Fabry Disease
Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients
The objective of CLI-06657AA1-03 (formerly PB-102-F51) is to evaluate the long-term safety, tolerability, and efficacy of 2 mg/kg pegunigalsidase alfa administered intravenously every four weeks in adult Fabry patients who have…
- Trial name
- NCT03614234
- Testing
- pegunigalsidase alfa
- Where
- 14 sites in United States, Belgium and 5 more
- Volunteers
- 29 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis
Study of WAL0921 in Patients With Glomerular Kidney Diseases
This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and…
- Conditions
- Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy
- Trial name
- NCT06466135
- Testing
- WAL0921
- Where
- 50 sites in United States, Australia and 5 more
- Volunteers
- 96 people
- Sponsor
- Walden Biosciences
Chronic Kidney Disease, Unspecified
Paricalcitol on Albuminuria, Inflammation and Fibrosis on Proteinuric Chronic Renal Diseases (PALIFE Study)
The purpose of this study is to estimate the differences between albuminuria values determined as Urine Albumin-to-Creatinine Ratio (UACR)(log transformed) from baseline to last observation caused by paricalcitol between the…
- Trial name
- PALIFE (NCT01820078)
- Testing
- Experimental arm, Comparator Arm
- Where
- 25 sites in Spain
- Volunteers
- 127 people
- Sponsor
- Fundación Renal Iñigo Alvarez De Toledo
Nephrotic Syndrome in Children, Steroid-Dependent Nephrotic Syndrome
Reduce Immunosuppression With Atmp in NS ChildrEn
A phase II open-label, single arm study aimed to ascertain whether infusions of cord-blood mesenchymal stromal cells (CB-MSCs) allow to reduce or suspend the chronic immunosuppressive therapy (IS) in steroid-dependent nephrotic…
- Conditions
- Nephrotic Syndrome in Children, Steroid-Dependent Nephrotic Syndrome, Idiopathic Nephrotic Syndrome
- Trial name
- RACE (NCT04034316)
- Testing
- Cord-blood mesenchymal stromal cells
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Autosomal Dominant Polycystic Kidney Disease (ADPKD
Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney Disease
The goal of this project is to measure the prevalence of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and hypertension in the general population of children and young people at risk of ADPKD, using magnetic resonance…
- Trial name
- HIYA-PKD (NCT07260071)
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- King's College London
Hypertension
Valsartan/Hydrochlorothiazide Combination vs Amlodipine in Patients With Hypertension, Diabetes, and Albuminuria.
The purpose of this study is assess if treatment with valsartan and a diuretic, hydrochlorothiazide, has beneficial effects in people with high blood pressure, diabetes, and albuminuria (protein in the urine) compared with…
- Trial name
- NCT00171561
- Testing
- valsartan/hydrochlorothiazide
- Where
- Switzerland
- Volunteers
- 144 people
- Sponsor
- Novartis
Obesity, Non-diabetic Chronic Kidney Disease
SGLT2 Inhibitors in Glomerular Hyperfiltration
Glomerular hyperfiltration is a major risk factor for accelerated glomerular filtration rate (GFR) decline and renal and cardiovascular events despite optimized conservative therapy with blood pressure and blood glucose (in…
- Trial name
- EMPATHY (NCT04143581)
- Testing
- Empagliflozin 10 MG
- Sponsor
- Mario Negri Institute for Pharmacological Research
CKDu, Arterial Stiffness
An Investigation Into the Cardiovascular Risk and Aetiology of CKDu in Sri Lanka
1. We hypothesise that CKDu patients will have increased arterial stiffness and thus increased all-cause and cardiovascular mortality.
- Conditions
- CKDu, Arterial Stiffness, Proteinuria, Serum Creatinine
- Trial name
- NCT02226055
- Testing
- Arterial Stiffness Assessment
- Where
- Sri Lanka
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
IGA Nephropathy, Proteinuria
Safety Study of of Intravenous CCL2-LPM in Patients With IgA Nephropathy
The purpose of this study is to evaluate the safety of several dose levels of CCL2-LPM in patients with IgA Nephropathy who have high levels of protein in the urine.
- Trial name
- NCT00856674
- Testing
- OPL-CCL2-LPM
- Where
- 3 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Osprey Pharmaceuticals USA, Inc.
Proteinuria
Oral Paricalcitol in Renal Transplant Recipients for Reducing Albuminuria
The main objective of this study is to examine if paricalcitol may reduce progression of graft fibrosis and proteinuria in kidney transplant patients.
- Trial name
- NCT01694160
- Testing
- Paricalcitol
- Where
- Norway
- Volunteers
- 77 people
- Sponsor
- Oslo University Hospital
IgA Nephropathy, Proteinuria
Acthar on Proteinuria in IgA Nephropathy Patients
IgA nephropathy occurs when IgA-a protein that helps the body fight infections-settles in the kidneys. IgA deposits may cause the kidneys to leak blood and sometimes protein in the urine.
- Trial name
- NCT02382523
- Testing
- Acthar 80 unit injection
- Where
- United States
- Sponsor
- Baylor College of Medicine
Diabetic Nephropathy, Albuminuria
Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy
It is estimated that approximately 30% of patients with diabetes develop diabetic nephropathy. Diabetic nephropathy is a multifactorial progressive disease that occurs through various mechanisms such as hyperglycemia, oxidative…
- Trial name
- NCT02689778
- Testing
- Pirfenidone
- Where
- Mexico
- Volunteers
- 62 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Type 2 Diabetes, Diabetic Nephropathy
Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes
Background: SGLT2 inhibitors are the first antiglycaemic drugs with a direct renal action. A part from reducing blood glucose, systemic blood pressure and albuminuria are decreased, while natriuresis is increased.
- Trial name
- DapKid (NCT02914691)
- Testing
- Dapagliflozine 10 mg once daily tablet treatment
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Peter Rossing
Chronic Kidney Disease, Hypertension
Early Identification and Action in CKD
Chronic kidney disease (CKD) is highly prevalent and associated with significantly increased risk of cardiovascular morbidity and end-stage renal disease.
- Trial name
- NCT02208674
- Testing
- Protocolized, pharmacist-delivered CKD Action Plan
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Geisinger Clinic
Focal Segmental Glomerulosclerosis, Nephrotic Syndrome
Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure
The investigators are trying to learn more about the cause of kidney diseases such as Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic syndrome by studying genetics.
- Conditions
- Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, End Stage Renal Disease, Kidney Failure
- Trial name
- FSGS (NCT02194582)
- Where
- United States
- Volunteers
- 2,050 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Immunoglobulin A Nephropathy, IgAN
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.
- Trial name
- I CAN (NCT06291376)
- Testing
- Ravulizumab
- Where
- 246 sites in United States, Argentina and 26 more
- Volunteers
- 584 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Chronic Kidney Disease, Proteinuria
Endothelin Receptor Antagonism in Proteinuric Nephropathy
The number of people with kidney problems is increasing rapidly, related in part to the increasing prevalence of diabetes. Patients with kidney problems tend to have protein leaking into the urine (proteinuria).
- Trial name
- NCT00722215
- Testing
- BQ-123 (selective endothelin A receptor antagonist), 0.9 % saline, Nifedipine
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- University of Edinburgh
Liver Transplant; Complications
Proteinuria in Liver Transplantation, a Single Egyptian Center Study
Proteinuria has been suggested to be a predictive factor and an important tool for differentiating the etiology of renal dysfunction in various clinical scenarios .The good predictive performance of preoperative proteinuria…
- Trial name
- NCT05733754
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Assiut University
Diabetes
Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in 20,000 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or fish oil (1 gram of omega-3 fatty…
- Trial name
- VITAL-DKD (NCT01684722)
- Testing
- Vitamin D, Omega-3 fatty acids (fish oil)
- Where
- United States
- Volunteers
- 1,312 people
- Sponsor
- University of Washington